## SUPPORTING INFORMATION

	•	•
Gene	Forward $(5' \rightarrow 3')$	Reverse $(5' \rightarrow 3')$
m-TNFa	CTACTCCCAGGTTCTCTTCAA	GCAGAGAGGAGGTTGACTTTC
m-ICAM1	GTGGCGGGAAAGTTCCTG	CGTCTTGCAGGTCATCTTAGGAG
m-CXCL16	CGTTGTCCATTCTTTATCAGGTTCC	TTGCGCTCAAAGCAGTCCA
m-ADAMTS5	GGCATCATTCATGTGACACC	CGAGTACTCAGGCCCAAATG
m-IL-17	TTCATGTGGTGGTCCAGCTTTC	CCTCAGACTACCTCAACCGTTC
m-MMP-13	CTTGATGCCATTACCAGTC	GGTTGGGAAGTTCTGGCCA
m-iNOS	AACGGAGAACGTTGGATTTG	CAGCACAAGGGGTTTTCTTC
m-COX-2	TGAGCAACTATTCCAAACCAGC	GCACGTAGTCTTCGATCACTATC
m-RANKL	ATGATGGAAGGCTCATGGTTGG	CAGCATTGATGGTGAGGTGTG
m-IL-1β	CTCCACCTCAATGGACAGAA	GCCGTCTTTCATTACACAGG
m-IL-6	GTATGAACAACGATGATGCACTTG	ATGGTACTCCAGAAGACCAGAGGA
m-MCP-1	AAGTCCCTGTCATGCTTCTG	TCTGGACCCATTCCTTCTTG
m-GAPDH	TGGCAAAGTGGAGATTGTTGCC	AAGATGGTGATGGGCTTCCCG

Supplemental Table 1: The primer sequences for the quantitative real-time PCR were:



**Figure S1.** [<sup>35</sup>S]-GTP $\gamma$ S binding stimulated by CP-55,940 (10<sup>-4</sup>-10<sup>-11</sup>M) in the absence or presence of  $\Delta^9$ -THCA-A (10<sup>-13</sup> or 10<sup>-6</sup>M). Data were expressed as mean ± SEM of at least three experiments performed in triplicate for each point, and were assessed by a two-way ANOVA followed by Bonferroni's posthoc test to compare CP-55,940 + $\Delta^9$ -THCA-A vs. CP-55,940 alone



-- Control -- CIA -- T0070907(CIA) -- SR141716(CIA)



**Figure S2.** Effect of administration of CB<sub>1</sub> and PPAR $\gamma$  antagonists in a CIA model. (A) Cumulative body weight change and (B) clinical scores in control mice, CIA-induced mice and treated mice during the treatment; values are referenced at the beginning of treatment (taken as 0). Measurement of paw swelling using a (C) plethysmometer and a (D) caliper at the end of the two-week treatment period. Data are means  $\pm$  SEM (n= 5 mice per group). For (A, B) \*p<0.05 CIA mice vs. control mice; for (C, D) \*p<0.05.



**Figure S3.** Effect of CB<sub>1</sub> and PPAR $\gamma$  antagonists on knee joints of the hind limbs in CIA mice. (A) Representative hind paw images and joint sections with H&E, safranin O and toluidine blue staining (Original magnification 40X). (B) Scoring of histological inflammation was determined using the criteria described in material and methods. (C) Cartilage damage was evaluated based on safranin O and toluidine blue staining according to the criteria described in materials and methods. Data are presented as mean  $\pm$  SEM (n=5). \*p<0.05.



**Figure S4.** Rigid (receptor) top docking results of  $\Delta^9$ -THCA-A, 11-OH- $\Delta^9$ -THCA-A and 2-AG to the orthosteric site of CB<sub>1</sub> X-RAY structure PDB 5XR8. Residues interacting with ligands are shown and important residues identified by mutagenesis experiments are depicted in red sticks and labeled with an asterisk. Color coding for  $\Delta^9$ -THCA-A, 11-OH- $\Delta^9$ -THCA-A and 2-AG are in green, yellow and pink, respectively